Aksu Tolga, Güler Tümer Erdem, Yalın Kıvanç, Gölcük Şükriye Ebru, Özcan Kazım Serhan
Department of Cardiology, Kocaeli Derince Education and Research Hospital; Kocaeli-Turkey.
Department of Cardiology, Bayrampaşa Kolan Hospital; İstanbul-Turkey.
Anatol J Cardiol. 2016 Sep;16(9):707-12. doi: 10.14744/AnatolJCardiol.2016.7100.
Septal reduction therapy is accepted as a first therapeutic option for symptomatic drug-resistant hypertrophic obstructive cardiomyopathy (HOCM). Although, surgical septal myectomy is the gold standard method, alcohol septal ablation is a well-studied alternative approach in the patients with suitable anatomy. Endocardial septal ablation (ESA) therapy was relatively new defined modality and outcomes of the procedure were not clearly elucidated yet. We aimed to review the clinical aspects of ESA procedure and provide some historical background.
间隔减容治疗被公认为是有症状的药物难治性肥厚性梗阻性心肌病(HOCM)的首选治疗方法。虽然外科间隔心肌切除术是金标准方法,但酒精间隔消融术是一种在解剖结构合适的患者中经过充分研究的替代方法。心内膜间隔消融术(ESA)是一种相对较新定义的治疗方式,该手术的结果尚未明确阐明。我们旨在回顾ESA手术的临床情况并提供一些历史背景。